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Abstract: Nanoparticles are useful delivery vehicles for promising drug candidates that face 
obstacles for clinical applicability. Sirolimus, an inhibitor of mammalian target of rapamycin 
has gained attention for targeted anticancer therapy, but its clinical application has been limited 
by its poor solubility. This study was designed to enhance the feasibility of sirolimus for human 
cancer treatment. Polymeric nanoparticle (PNP)–sirolimus was developed as an injectable for-
mulation and has been characterized by transmission electron microscopy and dynamic light 
scattering. Pharmacokinetic analysis revealed that PNP–sirolimus has prolonged circulation in the 
blood. In addition, PNP–sirolimus preserved the in vitro killing effect of free sirolimus against 
cancer cells, and intravenous administration displayed its potent in vivo anticancer efficacy in 
xenograft tumor mice. In addition, PNP–sirolimus enhanced the radiotherapeutic efficacy of 
sirolimus both in vitro and in vivo. Clinical application of PNP–sirolimus is a promising strategy 
for human cancer treatment.
Keywords: sirolimus, polymeric nanoparticle, anticancer, radiotherapy
Nanomedicine for diagnostic and therapeutic applications represents an innovative 
trend in cancer care.1 Nanoparticles are useful as drug delivery vehicles due to numerous 
advantages, such as improving drug solubility and stability in serum, extending drug 
circulation time, enhancing drug bioavailability, and reducing drug toxicity and side 
effects.2,3 Nontoxic and biodegradable polymers composed of amphiphilic block copo-
lymers are emerging as powerful drug-delivery vehicles for hydrophobic drugs.
The mammalian target of rapamycin (mTOR) pathway plays a key role in cel-
lular growth, proliferation, and homeostasis.4 Since mTOR-mediated signaling is 
frequently upregulated in tumor cells, and inhibition of this pathway induces apop-
totic and autophagic cell death of tumor cells, mTOR has been an attractive target for 
anticancer drug development.5,6 Sirolimus (Rapamune®; Pfizer, New York City, NY) 
is a US Food and Drug Administration (FDA)-approved mTOR inhibitor currently 
used to prevent the rejection of solid organ transplants.7 Recently, it was reported that 
sirolimus has antiproliferative and antiangiogenic properties in a variety of tumor cell 
lines. In addition, other mTOR inhibitors (CCI-779, RAD001, and AP23575) have 
been evaluated as anticancer therapies against various tumors.8–11 While early clinical 
trials suggest promising anticancer activity,9,12 the clinical development of sirolimus 
has been hindered by its pharmacokinetical limitations.
Sirolimus is a strongly hydrophobic drug. Consequently, injectable formulations 
of sirolimus are difficult to prepare and, as a result, sirolimus is only available in oral 
formulations. However, its oral bioavailability is only about 17%.13 Therefore, it is 
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restrictively suitable for low-dosage treatment, such as immu-
nosuppression in renal and liver transplant recipients.14 These 
are the potential drawbacks for delivery of sirolimus by 
conventional dosage formulations.
Since cancer is caused by multiple events, combinational 
modalities may provide better responses to cancer therapy. 
Combination treatments of irradiation and chemotherapeutic 
agents that increase sensitivity to radiation enhance 
therapeutic efficacy with minimal side effects. In this study, 
we report a formulation of sirolimus that does not require 
organic co-solvents or surfactants for solubility using a 
diblock copolymer. Polymeric nanoparticle-containing 
sirolimus (PNP–sirolimus) shows improved pharmacokinetic 
characteristics, potent antitumor activity, and yielded 
superior results on tumor growth inhibition, especially in 
combination with radiation.
Materials and methods
Preparation of sirolimus-incorporated 
polymeric nanoparticles
PNP–sirolimus was prepared by a simple fabrication method 
using a diblock copolymer, polyethylene glycol–poly-l-lactic 
acid (mPEG–PLA), monovalent metal salt of a biodegradable 
polyester (D,L-PLACOONa), and calcium chloride as 
described previously.15 Briefly, mPEG–PLA (Mn = 2.0–
1.8 KD; 1650 mg), D,L-PLACOONa (Mn = 1.5 KD; 825 mg), 
and sirolimus (25 mg) were completely dissolved in 1.5 mL of 
dichloromethane to obtain a clear solution. Dichloromethane 
was removed on a rotary evaporator under reduced pressure 
to produce a polymer–drug matrix. Distilled water was added 
to the matrix and the mixture was stirred for 30 minutes at 
50°C, resulting in a mixed polymeric micelle (mPM) solution. 
To produce the ionically-fixed polymeric nanoparticles, an 
aliquot of a 100 mg/mL solution of calcium chloride was 
added to the mPM solution, and the mixture was stirred for 
5 minutes at room temperature. D-Mannitol (20%, w/w) 
aqueous solution was added to the polymeric nanoparticle 
solution and was stirred for 5 minutes at room temperature. 
The solution was passed through a 0.22 µm poly(vinylidene 
fluoride) (PVDF) membrane filter. The filtered solution 
was freeze-dried and stored in a refrigerator until use. The 
sirolimus content was determined by high-performance liquid 
chromatography (HPLC) (Hewlett Packard series 1100; 
Hewlett Packard, Palo Alto, CA).
Polymeric nanoparticle characterization
Morphological examination of the polymeric nanopar-
ticles was performed by transmission electron microscopy 
(CM-30; Philips, Eindhoven, The Netherlands). The particle 
size and zeta potential of the PNPs were measured by laser 
light scattering (Nano ZS; Malvern Instruments, Malvern, 
United Kingdom).
Pharmacokinetic study
Male Sprague-Dawley (SD) rats each received a single 
intravenous dose of 10 mg/kg of sirolimus or PNP–sirolimus 
and underwent whole blood collections for 48 hours. Serial 
sirolimus whole blood concentrations (ng/mL) were mea-
sured by HPLC with tandem mass spectroscopy (MS/MS). 
For this, 0.3 mL of whole blood (three samples per group) 
was collected at 0, 15, and 30 minutes and 1, 2, 4, 8, 24, and 
48 hours after administration of sirolimus or PNP–sirolimus. 
Blood samples were centrifuged within 30 minutes of 
  collection and plasma samples (0.15 mL) were loaded onto 
a Zorbax XDB-C18 column (2.1 × 100 × 3.5 mm) (Agilent, 
Santa Clara, CA). Separations were conducted using two 
solvent systems composed of methanol/ammonium sulfate 
buffer (99:1, v/v). The flow rate was 0.3 mL/min. Tacrolimus 
was used as the internal standard for calibration and   quality 
control. All experiments were performed following the 
protocol approved by the Institutional Animal Care and Use 
Committee of the Asan Institute for Life Science.
Cell culture
Human lung adenocarcinoma A549 and human breast 
adenocarcinoma MCF7 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (Gibco-Invitrogen, Carlsbad, CA). 
Human non-small cell lung cancer NCI-H460 and human 
metastatic breast cancer MDA-MB-231 cells were maintained 
in RPMI 1640 medium (Gibco-Invitrogen). Both media were 
supplemented with 10% fetal bovine serum (Gibco-Invit-
rogen) and 1% penicillin/streptomycin under a humidified 
atmosphere of 5% CO2 and 95% air at 37°C.
Cell proliferation assay
Cells in exponential growth were harvested and plated 
in 96-well plates (10,000 cells/well in 100 mL of growth 
medium). Each treatment condition was performed in 
  triplicate. Cells were incubated overnight, and sirolimus or 
PNP–sirolimus was added to the media. Cells were incubated 
at 37°C for 48 hours and then processed for the CCK-8 
assay (Dojindo Molecular Technologies, Gaithersburg, MD) 
according to the manufacturer’s instructions. After incubation 
of cells with the CCK-8 reagent for 2 hours, absorbance at 
450 nm was measured using a spectrophotometer. To assess 
the radiosensitization effects, A549 cells were plated in 
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96-well culture plates 1 day before treatment and treated 
with PNP–sirolimus (100 nM) only or in combination with 
radiation (2 or 5 Gy). At 24 and 48 hours after radiation, cell 
viability was evaluated using the CCK-8 assay. Cells grown 
in normal culture medium were used as a control for all other 
samples. Considering the average growth in this control 
group as 1, relative cell proliferation was calculated.
In vitro clonogenic assay
A clonogenic assay was used to determine the proliferative 
potential of a cell population by testing the ability of single 
cells to form colonies in vitro.16 Colony formation was 
analyzed by plating 300 cells (sirolimus or PNP–sirolimus) or 
50 cells (control or PNP) per well in six-well culture plates. 
Cells were treated with sirolimus (30 nM), PNP–sirolimus 
(30 nM), PNP, or saline. For radiosensitizing-effect 
analysis, cells were irradiated with 0 to 10 Gy. At 2 hours 
postradiation, cells were treated with 30 nM of sirolimus, 
PNP–sirolimus, PNP, or saline and then incubated at 
37°C for 14 days. Colonies were stained with 0.5% crystal 
violet (Sigma-Aldrich, St Louis, MO) in methanol. Stained 
colonies were washed with water, air-dried, and counted 
when they consisted of more than 50 cells. The surviving 
fraction was calculated as (mean colonies counted)/[(cells 
plated) × (plating efficiency)], where plating efficiency was 
defined as (mean colonies counted)/(cells plated). All values 
were normalized to untreated cells. The mean number of 
colonies from triplicates and their standard deviations were 
calculated.
In vivo tumor growth delay
A549 cells were used as a xenograft model in male athymic 
nude mice (nu/nu; 6 weeks old; Japan SLC, Hamamatsu, 
Japan).17 A suspension of 1 × 106 cells in a 50 mL volume 
was injected subcutaneously (sc) into the right hindlimb of 
mice. Tumors were grown for 2 weeks until average tumor 
volume reached 70∼80 mm3. Mice were then divided into 
groups (6 mice per group). Treatment groups consisted 
of control, PNP, and PNP–sirolimus. Mice were treated 
with 20 mg/kg of PNP–sirolimus by intravenous (iv) 
injection three times per week for 4 weeks or once per week 
for 4 weeks. Body weights and tumor volumes were moni-
tored during the course. For analysis of radiosensitization, 
the radiation groups received 10 Gy of radiation fractionated 
over 5 consecutive days (from days 1 to 5) using a 6 MV 
X-ray from linear accelerators (CL/1800; Varian Medical 
System, Palo Alto, CA) in combination with 5 mg/kg of 
PNP–sirolimus. Tumor volume was calculated using the 
formula V = (L × W2) × 0.5, where V = volume, L = length, 
and W = width. The results were expressed as the mean ± 
standard deviation.   Statistical analysis was performed using 
the Mann–Whitney test, and P values of 0.005 or less were 
considered statistically significant. All experiments were 
performed following the protocol approved by the Institu-
tional Animal Care and Use Committee of the Asan Institute 
for Life Science.
Western blot analysis
Proteins were separated by gel electrophoresis on a sodium 
dodecyl sulfate–polyacrylamide gel and then transferred 
to PVDF membranes. The membranes were blocked with 
Tris-buffered saline containing 0.1% Tween-20 (TBST) and 
5% (w/v) skim milk.18 After being washed with TBST, the 
membranes were incubated overnight at 4°C with a phospho-
p70S6K or p70S6K antibody (R&D systems,   Minneapolis, 
MN) diluted with TBST containing 1% skim milk. After 
washing with TBST, the membranes were incubated for 
1 hour at room temperature with the secondary antibody 
(Jackson ImmunoResearch Laboratories, West Grove, PA). 
Bands were detected by an ECL system. The LC3 antibody 
was purchased from Novus Biologicals (Littleton, CO).
Results
Preparation of polymeric nanoparticles
Most approaches for the preparation of polymeric nanospheres 
using amphiphilic block copolymers, such as emulsification or 
nanoprecipitation, are complex and time-consuming processes 
that present difficulties for large-scale production.19,20 In 
addition, the resulting nanospheres from these techniques 
have a large particle size and wide size distribution makes 
sterile filtration difficult. Previously, we reported that mPEG–
PLA and D,L-PLACOONa could form mixed polymeric 
micelles.21 In addition, a stable metal ion-fixed polymeric 
nanoparticle (PNP) could be prepared using CaCl2, due to 
the electrostatic interaction between D,L-PLACOO- and 
Ca2+, forming a complex of (D,L-PLACOO)2Ca2+ in aqueous 
solution. This water-soluble biopolymer is biodegradable 
and biocompatible.15 PNP can solubilize 0.2∼10 mg/mL 
concentrations of sirolimus in normal saline. PNP or PNP–
sirolimus was highly monodispersed (Figure 1A and B). 
The smooth surfaces and spherical shape topology of PNPs 
were confirmed by transmission electron microscopy (TEM). 
Dynamic light scattering (DLS) analysis revealed that the 
PNP had a unimodal size distribution with an average 
hydrodynamic diameter of 34.95 nm having PDI 0.236 and 
a negative zeta potential of -2.96 mV (Figure 1C; Table 1). 
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Table 1 Characterization of PNP nanoparticles for particle size, 
zeta potential, and PDI
Formulation Particle size  
(nm)
PDI Zeta potential   
(mV)
PNP vehicle 34.95 0.236 -2.96
PNP–sirolimus 37.83 0.153 -1.85
Abbreviations: PDI, Polydispersity Index; PNP, polymeric nanoparticle.
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Figure 1 TEM image and hydrodynamic size distribution of (A and C) PNP and (B and D) PNP–sirolimus. 
Abbreviations: PNP, polymeric nanoparticle; TEM, transmission electron microscopic.
A small increase in size (from 34.95 to 37.83 nm) and zeta 
potential (from -2.96 to -1.85 mV) was observed following 
sirolimus encapsulation to PNP (Figure 1D; Table 1).
Pharmacokinetic characterization  
of PNP–sirolimus
To determine whether PNP–sirolimus shows therapeutic 
advantages over the free drug, we performed a pharmacoki-
netic study. Using the same dose (10 mg/kg), noncompart-
mental pharmacokinetic values of the area under the curve 
(AUC), the maximum measured drug concentration (Cmax), 
the time of peak concentration measured (Tmax), and the 
absolute bioavailability (F) were calculated from plasma 
drug concentration–time data (Figure 2). Detectable plasma 
concentrations of sirolimus persisted for 48 hours in rats 
treated with PNP–sirolimus. As shown in Table 2, the Tmax 
was the same at 0.25 hours for both free sirolimus and PNP–
sirolimus, whereas PNP–sirolimus yielded a significantly 
higher Cmax in plasma compared to free sirolimus. A distinct 
increase in sirolimus concentration was evident at 24 hours 
on a semi-log concentration time profile after the adminis-
tration of PNP–sirolimus. Also, PNP–sirolimus provided 
∼3-fold higher F values in blood compared to free sirolimus. 
Compared to other administration methods, the Cmax and AUC 
were highest on iv PNP–sirolimus (data not shown). Thus, 
the pharmacokinetic characteristics of PNP–sirolimus were 
considerably improved compared with free sirolimus.
In vitro anticancer efficacy  
of PNP–sirolimus
To investigate the cytotoxic effect of PNP–sirolimus 
against human cancer cells, human lung cancer A549 
and NCI-H460 cells and human breast cancer MCF7 and 
MDA-MB-231 cells were incubated for 48 hours with PNP, 
PNP–sirolimus, or sirolimus. PNP–sirolimus reduced the 
proliferation rate of cancer cells by approximately 20% in the 
case of A549 and MCF7 cells exposed to 500 nM (Figure 3A). 
The extent of growth inhibition of PNP–sirolimus was similar 
to that of free sirolimus. For the management of breast cancer, 
the expression level of estrogen receptor (ER) is an important 
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predictive and prognostic factor. PNP–sirolimus displayed 
similar growth inhibition in ER-positive breast cancer 
MCF-7 and ER-negative breast cancer MDA-MB231 cells. 
To evaluate the prolonged effects of PNP–sirolimus on 
cancer cell survival, a clonogenic assay was performed. 
A marked decrease in the survival rate of cells treated with 
PNP–sirolimus or sirolimus was shown in all cancer cell 
lines (Figure 3B). These results indicate that PNP–sirolimus 
preserved the cytotoxic effect of sirolimus and exerts potent 
anticancer effects in human cancer cells.
To explore whether the anticancer effect of PNP–
sirolimus occurs through inhibition of the mTOR pathway, 
we examined the effect of PNP–sirolimus on the phospho-
rylation of the downstream target p70S6K at Thr389 in 
A549 cells. As shown in Figure 3C, p70S6K was phospho-
rylated in normal conditions, which indicates activation of 
the mTOR-mediated signaling pathway. As expected, the 
phosphorylation of the downstream effector p70S6K was 
significantly decreased by PNP–sirolimus, suggesting that 
PNP–sirolimus effectively inhibits mTOR signaling in a 
dose-dependent manner.
In vivo anticancer efficacy  
of PNP–sirolimus
The in vivo anticancer effect of PNP–sirolimus was evalu-
ated in a xenograft mouse model bearing A549 tumors. 
To examine the therapeutic activity of PNP–sirolimus as a 
single agent without toxicity, mice were treated with PNP–
sirolimus (20 mg/kg) by iv injection three times per week for 
4 weeks or once per week for 4 weeks. Tumor volume and 
body weight were monitored during the course of the experi-
ment to determine therapeutic efficacy and toxicity. In the 
control group, the volume of tumors on day 41 was ninefold 
larger than that of day 1, while the tumor volume of the group 
treated with PNP–sirolimus was only 1.5-fold higher at three 
treatments per week, and threefold at one treatment per week 
(Figure 4A and C). The anticancer effect of PNP–sirolimus 
was observed starting on day 6 after treatment (P , 0.005) 
and sustained until termination of both experiments. During 
the experiment, iv drug treatment was well-tolerated, and 
there was no apparent toxicity throughout the study as evalu-
ated by body weight changes (Figure 4B and D).
In vitro radiosensitization  
by PNP–sirolimus
Radiation therapy is employed extensively for treatment of 
almost all types of solid tumors. The use of molecularly-
targeted agents in combination with ionizing radiation 
(IR) is a promising therapeutic strategy against cancer. 
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Figure 2 Pharmacokinetic characterization of PNP–sirolimus. 
Notes: Plasma concentration-time profiles were determined in Sprague–Dawley rats iv injected with sirolimus (solid square) or PNP–sirolimus (open diamond) at a dose of 
10 mg/kg. Experimental points are the means of the observed plasma levels (mean ± SD, n = 3 per group). 
Abbreviations: PNP, polymeric nanoparticle; iv, intravenous.
Table 2 Pharmacokinetic parameters in Sprague–Dawley rats 
following intravenous injection of sirolimus or PNP–sirolimus
PK parameter Free sirolimus  
(iv)
PNP–sirolimus 
(iv)
AUClast (µg ⋅ hours/mL) 5366.7 16,901.7
Cmax (µg/mL) 2890 11,303.3
Tmax (hours) 0.25 0.25
F (%) 100 315
Abbreviations: AUC, area under the curve; Cmax, peak plasma concentration; F, 
absolute bioavailability; iv, intravenous; PNP, polymeric nanoparticle; Tmax, time to 
peak plasma concentration.
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Figure 3 (Continued)
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Increasing evidence now indicates that mTOR inhibitors 
have radiosensitizing effects.22–24 To determine whether 
PNP–sirolimus sensitizes A549 cell lines to radiation therapy, 
CCK-8 and clonogenic assays were performed. Co-treatment 
of PNP–sirolimus with IR enhanced the radiation-induced 
cytotoxicity compared with single use of PNP–sirolimus 
(Figure 5A). A clonogenic assay showed that combined 
treatment of PNP–sirolimus and IR resulted in enhanced radi-
osensitivity, although no significant difference was observed 
between PNP–sirolimus and free sirolimus (Figure 5B).
It is known that mTOR inhibition confers radiosen-
sitivity and induces the nonapoptotic cell death   pathway 
of autophagy.22 We investigated whether treatment with 
PNP–sirolimus in combination with IR induces autophagic 
cell death in A549 cells. Autophagy correlated with increased 
expression of LC3II, which is an autophagosome formation 
marker.25 Western blot analysis was performed to detect the 
conversion of LC3I into LC3II. A significant increase in LC3II 
protein is shown in Figure 5C, suggesting that combined 
therapy of PNP–sirolimus and IR induces autophagic cell 
death by efficient inhibition of mTOR. We also assessed 
apoptosis by flow cytometry using annexin V and propidium 
iodide staining to confirm whether apoptotic cell death was 
involved. No increased annexin V staining portion was found 
0 C 51 0
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50 100 200 05 10 50 100 200 (nM)
p-p70S6K
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GAPDH
Figure 3 In vitro anticancer efficacy of PNP–sirolimus. (A) A549, NCI-H460, MCF7, and MDA-MB-231 cells were incubated with various concentrations of PNP–sirolimus 
or sirolimus for 48 hours. (B) The cellular proliferation rate was measured by a CCK-8 assay. (C) The survival fraction was determined by a clonogenic assay. (D) Western 
blot analysis for total and phosphorylated p70S6K protein was performed with gAPDH as a loading control. 
Abbreviations: gAPDH, glyceraldehyde-3-phosphate dehydrogenase; PNP, polymeric nanoparticle.
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Figure 4 In vivo anticancer efficacy of PNP–sirolimus. (A) A549 tumor-bearing mice were treated with 20 mg/kg of PNP–sirolimus three times per week for 4 weeks by   
iv injection. Tumor volume was measured using a caliper (n = 6; *P , 0.005). (B) Body weight was monitored twice per week. (C) A549 tumor-bearing mice were treated 
with 20 mg/kg of PNP–sirolimus once per week for 4 weeks by iv injection (n = 6; *P , 0.005). (D) Body weight was monitored twice per week. 
Abbreviations: PNP, polymeric nanoparticle; iv, intravenous.
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in either PNP–sirolimus or free sirolimus, suggesting that 
cell death caused by these drugs was mainly independent on 
apoptosis (data not shown).
In vivo radiosensitization  
by PNP–sirolimus
As for the experiments showing the in vitro radiosensitiz-
ing effect of PNP–sirolimus, xenograft mice bearing A549 
tumors were employed to validate the in vivo radiosensitizing 
effect by iv injected PNP–sirolimus. Mice were treated with 
PNP–sirolimus (5 mg/kg), followed 2 hours later by IR (2 Gy) 
daily for 5 days. At the dose of 5 mg/kg, PNP–sirolimus alone 
showed a clear tumor growth delay comparable to that of IR 
treatment. Combination therapy with PNP–sirolimus and 
IR was significantly more effective than either IR or PNP–
sirolimus alone (Figure 6A) (n = 6; P , 0.005). There was 
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no obvious change in the weight of mice after treatments 
(Figure 6B). Therefore, PNP–sirolimus exerts a potent in vivo 
anticancer efficacy in xenograft tumor animals, especially 
when it is combined with radiation.
Discussion
Drug-delivery systems can improve several crucial properties 
of free drugs, such as solubility, stability, pharmacokinetics, 
biodistribution, and efficacy.26 Polymeric micelles or 
nanoparticles composed of biocompatible and biodegradable 
materials have been extensively explored as powerful drug-
delivery vehicles for cancer drug therapy. In this study, a new 
polymeric nanoparticle system was prepared by self-assembly 
of amphiphilic diblock copolymers to solubilize sirolimus in 
aqueous solutions.
mTOR was discovered in the early 1990s in studies on the 
mechanism of action of sirolimus, which was originally used 
as an antifungal agent and later recognized for its anticancer 
properties.9,27 Signaling through the mTOR pathway has been 
linked to growth, progression, and chemoresistance of several 
cancers and is hyperactivated in certain cancers,28–30 suggest-
ing mTOR as an attractive target for cancer therapy. Although 
the inhibition of mTOR by sirolimus is a promising anticancer 
strategy, its clinical applications have been hindered by its 
extremely low solubility in water (2.6 mg/mL).31,34 Sirolimus 
contains no functional groups that are ionizable in the pH 
range of 1–10 and is only slightly soluble in acceptable 
parenteral excipients, such as ethanol, propylene glycol, 
glycerine, polysorbate 80, and polyethylene glycol 400.32 
Attempts to develop an injectable formulation of sirolimus 
employing surfactants were not favorably evaluated due to 
vehicle toxicity. Consequently, previous attempts to develop 
iv formulations have been difficult, but have allowed for the 
development of currently employed oral solutions and tablet 
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Figure 6 In vivo radiosensitization by PNP–sirolimus. Athymic nude mice with A549 xenograft tumors were treated with PNP or PNP–sirolimus (5 mg/kg), followed 2 hours 
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formulations. To apply sirolimus to human cancer treatment, 
development of an injectable formulation is required. Recent 
approaches have been taken to improve the formulation 
and delivery of sirolimus. One of these approaches was the 
development of temsirolimus (CCI-779), a water-soluble 
sirolimus ester that has shown promise in early Phase I 
trials.33 However, its iv formulations require ethanol due to 
the limited solubility of CCI-779, even at 120 mg/mL, which 
may cause hemolysis.34
PNP composed of amphiphilic block copolymers with 
nontoxic and biodegradable polymers (mPEG–PLA and 
D,L-PLACOONa) is a powerful drug-delivery vehicle for 
hydrophobic drugs. PNP exhibited good water solubility 
for sirolimus (0.2∼10 mg/mL). In addition, iv-injected 
PNP–sirolimus was well tolerated in mice and rats. The 
PDI of samples demonstrates a unimodal size distribution 
(Figure 1, Table 1). Positively charged nanoparticles are 
known to be rapidly cleared from the bloodstream, making 
them undesirable for drug delivery. In contrast, the zeta 
potential of PNP–sirolimus was negative. Noncompartmental 
analysis of the blood concentrations showed a significant 
change in certain pharmacokinetic parameters of sirolimus 
in PNP–sirolimus compared to that of control free sirolimus 
(Figure 2, Table 2). Cmax and AUClast values were markedly 
increased, and the absolute bioavailability of PNP–sirolimus 
was threefold higher. According to our unpublished data, 
the AUC of PNP–sirolimus increased in a dose-dependent 
manner. Also, AUClast, Cmax, and F values were   greatest 
in iv-injected PNP–sirolimus compared to sc or oral 
  administration. Thus, PNP improved the pharmacokinetic 
characteristics of sirolimus.
In addition, there may be increasing accumulation of 
PNP–sirolimus at the tumor site because tumor-targeting 
nanoparticles have enhanced permeability and retention 
(EPR), which results from the disordered, leaky vasculature of 
the tumor.35 To avoid filtration by the kidneys or drug removal 
by the liver, nanocarriers need to be larger than 10 nm and 
smaller than 100 nm. PNP–sirolimus has a suitable size 
(38 nm) for effective delivery and accumulation in tumors. 
Indeed, the EPR effect will be more effective if nanocarriers 
circulate for a long period. A common method to protect 
nanocarriers from the reticuloendothelial system is coating 
the surface of the particles with PEG. PNP–sirolimus was also 
coated with PEG molecules by mPEG–PLA during polymer 
production, which contributes to the increased circulation 
time of PNP–sirolimus.
Previous studies have shown that sirolimus acts as a 
cytostatic agent by arresting the cell cycle.29 PNP–sirolimus 
had a similar cytotoxicity to the free drug, but showed 
low cytotoxicity (∼20%) in cancer cell lines (Figure 3A). 
Although tumor cells were not immediately killed by 
sirolimus, the affected clones did not grow continually. 
A marked decrease in the survival curve of PNP–sirolimus-
treated cells was seen in a clonogenic assay (Figure 3B). We 
also found that combined treatment of PNP–sirolimus and 
IR slightly enhanced radiosensitivity in clonogenic assays 
as compared to either agent alone in vitro (Figure 5B), while 
it led to a significant in vivo tumor growth delay in the 
human lung cancer A549 xenograft tumor model (Figure 6). 
Although we were not able to compare the effect of PNP–
sirolimus to that of the free drug in vivo due to the lack of a 
soluble formulation when free, the pharmaceutical activity 
of sirolimus when combined with PNP was well preserved 
as it was evident that the effect of the PNP–sirolimus is very 
similar to that of the free sirolimus in in vitro results. The 
remarkable in vivo anticancer and radiosensitization effect 
could be explained by the EPR effect of PNP–sirolimus. To 
exclude the possible influence of the PNP vehicle itself on 
cell viability, various concentrations of PNP vehicle were 
incubated for 72 hours with A549 cells, and cell viability was 
assessed. The PNP vehicle had no obvious adverse effect on 
cell viability (data not shown), demonstrating that the PNP 
vehicle itself has no cytotoxicity.
Recent cancer treatment usually involves combinations 
of different modalities in order to maximize the therapeutic 
outcome and to reduce side effects. Radiation therapy is 
employed extensively for treatment of almost all types of 
solid tumors. Despite recent advances in radiotherapy and 
chemotherapy, the mortality rate of certain cancers, such 
as lung cancer, remains high. Finding agents that sensitize 
tumor cells to radiation would increase the tumor response 
while allowing lower therapeutic doses to be used, thereby 
minimizing toxicity to surrounding organs. It is well known 
that mTOR inhibition induces autophagy, which is important 
in cancer development and progression.22 PNP–sirolimus 
and IR lead to enhanced radiosensitization via induction of 
autophagy in a nonsmall cell lung tumor xenograft model.
In this study, we developed a novel injectable formulation 
of sirolimus using PNP that consists of biodegradable, 
biocompatible polymers. This drug could be readily dispersed 
in physiological media without any surfactants or cosolvents. 
PNP–sirolimus showed improved pharmacokinetic features 
compared to free sirolimus. In addition, PNP–sirolimus 
effectively inhibited tumor cell proliferation and tumor 
mass growth and enhanced radiation-induced cell death 
by inhibition of the mTOR pathway and activation of 
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autophagy. Therefore, clinical application of the injectable 
PNP–sirolimus may be an attractive new therapeutic approach 
for cancer therapy.
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